These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 16267003

  • 1. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
    Ryan AE, Shanahan F, O'Connell J, Houston AM.
    Cancer Res; 2005 Nov 01; 65(21):9817-23. PubMed ID: 16267003
    [Abstract] [Full Text] [Related]

  • 2. Direct in vivo transfection of antisense Fas-ligand reduces tumor growth and invasion.
    Nyhus JK, Wolford C, Feng L, Barbera-Guillem E.
    Gene Ther; 2001 Feb 01; 8(3):209-14. PubMed ID: 11313792
    [Abstract] [Full Text] [Related]

  • 3. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer.
    O'Connell J, Bennett MW, O'Sullivan GC, Roche D, Kelly J, Collins JK, Shanahan F.
    J Pathol; 1998 Nov 01; 186(3):240-6. PubMed ID: 10211111
    [Abstract] [Full Text] [Related]

  • 4. Suppression of FasL expression in tumor cells and preventing tumor necrosis factor-induced apoptosis by adenovirus 14.7K is an effective escape mechanism for immune cells.
    Zhang J, Xu G.
    Cancer Genet Cytogenet; 2007 Dec 01; 179(2):112-7. PubMed ID: 18036397
    [Abstract] [Full Text] [Related]

  • 5. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
    Shimizu M, Fontana A, Takeda Y, Yagita H, Yoshimoto T, Matsuzawa A.
    J Immunol; 1999 Jun 15; 162(12):7350-7. PubMed ID: 10358186
    [Abstract] [Full Text] [Related]

  • 6. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
    Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F.
    J Immunol; 1998 Jun 01; 160(11):5669-75. PubMed ID: 9605174
    [Abstract] [Full Text] [Related]

  • 7. Antigen-specific CD8+ T lymphocytes generated from a DNA vaccine control tumors through the Fas-FasL pathway.
    Cheng WF, Lee CN, Chang MC, Su YN, Chen CA, Hsieh CY.
    Mol Ther; 2005 Nov 01; 12(5):960-8. PubMed ID: 15979942
    [Abstract] [Full Text] [Related]

  • 8. Fas ligand promotes tumor immune evasion of colon cancer in vivo.
    Ryan AE, Shanahan F, O'Connell J, Houston AM.
    Cell Cycle; 2006 Feb 01; 5(3):246-9. PubMed ID: 16418579
    [Abstract] [Full Text] [Related]

  • 9. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo.
    Yoshimoto Y, Kawada M, Ikeda D, Ishizuka M.
    Int Immunopharmacol; 2005 Feb 01; 5(2):281-8. PubMed ID: 15652759
    [Abstract] [Full Text] [Related]

  • 10. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells.
    Tada Y, O-Wang J, Seimiya M, Takiguchi Y, Tatsumi K, Kuriyama T, Tagawa M.
    Anticancer Res; 2002 Feb 01; 22(2A):831-6. PubMed ID: 12014659
    [Abstract] [Full Text] [Related]

  • 11. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
    Kim R, Emi M, Tanabe K, Uchida Y, Toge T.
    Cancer; 2004 Jun 01; 100(11):2281-91. PubMed ID: 15160330
    [Abstract] [Full Text] [Related]

  • 12. Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity.
    Tada Y, O-Wang J, Wada A, Takiguchi Y, Tatsumi K, Kuriyama T, Sakiyama S, Tagawa M.
    Cancer Gene Ther; 2003 Feb 01; 10(2):134-40. PubMed ID: 12536202
    [Abstract] [Full Text] [Related]

  • 13. Loss of functional Fas ligand enhances intestinal tumorigenesis in the Min mouse model.
    Fingleton B, Carter KJ, Matrisian LM.
    Cancer Res; 2007 May 15; 67(10):4800-6. PubMed ID: 17510409
    [Abstract] [Full Text] [Related]

  • 14. Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL).
    Drozdzik M, Qian C, Lasarte JJ, Bilbao R, Prieto J.
    Gene Ther; 1998 Dec 15; 5(12):1622-30. PubMed ID: 10023441
    [Abstract] [Full Text] [Related]

  • 15. Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells.
    Zhu Q, Liu JY, Yang CM, Xu HW, Zhang AZ, Cui Y, Wang HB, Qin CY, Li YQ.
    Eur J Gastroenterol Hepatol; 2006 Oct 15; 18(10):1071-7. PubMed ID: 16957513
    [Abstract] [Full Text] [Related]

  • 16. Immune privilege or inflammation? The paradoxical effects of Fas ligand.
    O'Connell J.
    Arch Immunol Ther Exp (Warsz); 2000 Oct 15; 48(2):73-9. PubMed ID: 10807046
    [Abstract] [Full Text] [Related]

  • 17. Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance.
    Shimonishi T, Isse K, Shibata F, Aburatani I, Tsuneyama K, Sabit H, Harada K, Miyazaki K, Nakanuma Y.
    Hepatology; 2000 Oct 15; 32(4 Pt 1):761-9. PubMed ID: 11003620
    [Abstract] [Full Text] [Related]

  • 18. T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells.
    Tada Y, O-Wang J, Takiguchi Y, Tatsumi K, Kuriyama T, Tagawa M.
    Int J Mol Med; 2002 Mar 15; 9(3):281-5. PubMed ID: 11836634
    [Abstract] [Full Text] [Related]

  • 19. B lymphocytes mediate Fas-dependent cytotoxicity in MRL/lpr mice.
    Bonardelle D, Benihoud K, Kiger N, Bobé P.
    J Leukoc Biol; 2005 Nov 15; 78(5):1052-9. PubMed ID: 16204618
    [Abstract] [Full Text] [Related]

  • 20. The "Fas counterattack" is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instability.
    Houston AM, Michael-Robinson JM, Walsh MD, Cummings MC, Ryan AE, Lincoln D, Pandeya N, Jass JR, Radford-Smith GL, O'Connell J.
    Hum Pathol; 2008 Feb 15; 39(2):243-50. PubMed ID: 17961631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.